AstraZeneca Furthers Ambition to Redefine Cancer Care with First Data from Four Major Pivotal Trials at ESMO 2025
AstraZeneca is scheduled to unveil initial data from four major pivotal cancer trials at the European Society for Medical Oncology (ESMO) Congress in October 202513.
Nearly 100 abstracts highlighting nine approved and nine potential new medicines, as well as pipeline candidates, will be presented, with 26 oral presentations and two late-breaking Presidential Symposium slots13.
Key studies to be showcased include two Phase III trials:
DESTINY-Breast11 and DESTINY-Breast05 (trastuzumab deruxtecan/Enhertu) targeting high-risk, HER2-positive early-stage breast cancer, and another Phase III trial of datopotamab deruxtecan (Datroway) for first-line treatment of locally recurrent or metastatic triple-negative breast cancer in patients not eligible for immunotherapy3.
A separate Phase III trial evaluates durvalumab (Imfinzi) in combination with standard bacillus Calmette-Guérin therapy for high-risk, non-muscle-invasive bladder cancer3.
AstraZeneca and Daiichi Sankyo are highlighted as market leaders in the antibody-drug conjugate (ADC) space, with positive survival data for Datroway distinguishing it from competitors in certain patient populations1.
Favorable results at ESMO could provide catalysts for new regulatory approvals, expanded indications, and significant revenue growth, with FDA approval anticipated for datopotamab deruxtecan by January 20251.
These presentations underscore AstraZeneca’s strategy to move beyond traditional chemotherapy with next-generation ADCs and immunotherapies, aiming to improve outcomes for diverse cancer types and settings4.
Practice-changing data are expected, which may redefine therapeutic standards for multiple solid tumor types, positioning AstraZeneca as a key innovator in the oncology sector134.
Sources:
1. https://www.edgen.tech/news/stock/astrazeneca-prepares-to-unveil-extensive-oncology-trial-data-at-esmo-congress
3. https://www.pharmtech.com/view/astrazeneca-cancer-care-contributions-highlighted-trial-data-esmo-congress
4. https://www.indianpharmapost.com/news/astrazeneca-advances-ambition-to-improve-standards-of-care-in-multiple-cancer-types-16125